CDC Recommends Ways to Increase CRC Screening

Share this content:
CDC Suggests Ways to Increase CRC Screening Rates
CDC Suggests Ways to Increase CRC Screening Rates

(HealthDay News) -- Various approaches should be implemented to increase the use of colorectal cancer (CRC) screening tests, according to the November issue of the U.S. Centers for Disease Control and Prevention's Vital Signs.

Related: Gastrointestinal Cancers Resource Center

Noting that CRC is the second leading cancer killer of U.S. men and women and that about 90% of people live 5 or more years when CRC is found early through testing, researchers from the CDC looked at ways to increase testing.

According to the report, about one in three adults (28%; 23 million) aged 50 to 75 years are not getting tested as recommended, and most of these adults (76%) are insured. To increase testing, health care providers should offer recommended test options (fecal occult blood test [FOBT], fecal immunochemical test [FIT], and sigmoidoscopy), with information about each test; match patients with the tests they are most likely to complete; work with health professionals to increase testing via hiring and training of patient navigators; and create ways to make it easy to get FOBT/FIT kits in places other than the doctor's office.

"Testing saves lives, but only if people get tested. Studies show that people who are able to pick the test they prefer are more likely to actually get the test done. Increasing the use of all recommended colorectal cancer tests can save more lives and is cost-effective," according to the report.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs